XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment Information (Tables)
6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Information regarding net sales and operating profit (loss) for the three months ended June 30, 2024 and 2023 are as follows (in millions):

Life
Science
Clinical
Diagnostics
Other
Operations
Net sales2024$250.5 $387.9 $0.1 
 2023$300.2 $380.1 $0.8 
Operating profit (loss)2024$19.1 $82.6 $(0.2)
 2023$28.0 $61.8 $(0.2)

Information regarding net sales and operating profit (loss) for the six months ended June 30, 2024 and 2023 are as follows (in millions):

Life
Science
Clinical
Diagnostics
Other
Operations
Net sales2024$492.2 $756.6 $0.5 
 2023$623.8 $732.2 $2.0 
Operating profit (loss)2024$10.9 $135.7 $(0.4)
 2023$63.7 $88.1 $(0.3)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following reconciles total operating profit to consolidated loss before income taxes (in millions):

Three Months EndedSix Months Ended
June 30,June 30,
 2024202320242023
Operating profit$101.5 $89.6 $146.2 $151.5 
Interest expense(12.3)(12.4)(24.5)(24.7)
Foreign currency exchange gains, net
1.7 1.3 3.7 3.6 
Losses from change in fair market value of equity securities and loan receivable(2,895.3)(1,595.4)(2,473.3)(1,612.9)
Other income, net18.1 16.5 52.7 66.9 
Consolidated loss before income taxes
$(2,786.3)$(1,500.4)$(2,295.2)$(1,415.6)